1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients.

Slides:

Advertisements

Similar presentations

A Retrospective Review Investigating the Feasibility of Acupuncture as a Supportive Care Agent in Children with Cancer Kathy Taromina, MS, LAc, Diane Rooney,

Advertisements

Dwight E. Heron, MD (on behalf of the Cancer Disparities Research Partnership) ASTRO Education Symposium November 6 th, 2006.

Dr. John E. Niederhuber Director, National Cancer Institute Board of Scientific Advisors June 22, 2009 NCI Director’s Update.

PLENARY SESSION Fall Group Meeting Miami, FL November 13, 2010.

CTSA Implementation at the University of Pennsylvania Carl June, M.D. Professor of Pathology and Lab Medicine Director of Translational Research Institute.

Guideline for Monitoring of Clinical Trials for Cooperative Groups, CCOP Research Bases, and the Clinical Trials Support Unit (CTSU) Lore Lagrone Program.

Advocating for Clinical Trial Accural

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.

 Lowell Smith Sr. Director, Business & Communication Research Administration Moffitt Cancer Center  Jeanine Stiles Chief Administrative Officer Associate.

Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.

Academic Clinical Trial Do’s & Don’ts for Partnering with Pharma CCAF San Diego, CA April 14, 2014 J. Eric Bubbers, Ph.D.

CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.

ACRIN Research Associates Educational Session Radiation Therapy Oncology Group Research Associates Committee Joyce Neading, RHIT, CTR Program Director,

Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.

1 The Cancer Consortium Deborah Schrag, MD (PI) Caprice Christian Greenberg, MD, MPH Brigham and Women’s Hospital Dana-Farber Cancer Institute.

Ginger for Chemotherapy-related Nausea in Cancer Patients Julie L. Ryan, PhD, MPH 1 C. Heckler, PhD 1, S.R. Dakhil, MD 2, J. Kirshner, MD 3, P.J. Flynn,

NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.

ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.

NEUROPROTECTIVE EFFECT OF PAROXETINE HYDROCHLORIDE AMONG 781 CANCER PATIENTS RECEIVING CHEMOTHERAPY: A URCC CCOP STUDY. Pascal Jean-Pierre, PhD, MPH University.

States’ Investments in Cancer Research The Cancer Institute of New Jersey Robert S. DiPaola M.D.

Developing Relationships: Cooperative Group Networking Developing Relationships: Cooperative Group Networking Kandie Dempsey, MS, RN, OCN, CCRP Delaware.

Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.

NCCCP Governance and Organization Maureen Johnson, Ph.D. NCCCP Project Officer Special Assistant to the Director June 25, 2007.

The Quantitative Imaging Network (QIN) Robert Nordstrom, Ph.D. Larry Clarke, Ph.D.

2011 ACRIN Annual Meeting The ACRIN Accrual Project at University of Washington Constance Lehman, MD. PhD David Mankoff, MD. PhD Tiffany Wong, MS.

Evidence-Based Journal Article Presentation [Insert your name here] [Insert your designation here] [Insert your institutional affiliation here] Department.

Sanford USD Medical Center Sioux Falls, SD Becky Nelson, Senior VP & COO Health Service Operations Sanford Health.

Overview of NCI Supported Fatigue Trials Ann O’Mara, PhD, RN, FAAN.

NCI-Sponsored Clinical Trials Andrea Denicoff, RN, MS, ANP 1 Worta McCaskill-Stevens, MD 2 Jo Anne Zujewski, MD 1 Jeff Abrams, MD 1 June 25, 2007 NCCCP.

The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Multicenter Clinical Trials George.

Gynecologic Oncology Group Gynecologic Oncology Group (GOG) Sharon Stockman, C-CRC The University of Iowa Hospitals Iowa City, IA Chair, GOG Data Management.

Clinical Research in a Community Practice Bob Behrens, MD Iowa Oncology Research Association (IORA)

Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.

1 National Cancer Institute Clinical Trial Cooperative Groups Perspectives from the National Surgical Adjuvant Breast and Bowel Project Joyce Mull, MPM.

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors.

MESOTHELIOMA SPECIALTY CARE CENTER (SCC) HILLMAN CANCER CENTER.

SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

ICTW Punta del Este, Uruguay Role of the Oncology Research Team.

Preclinical Guidelines: Development of Radioprotective/Mitigative Agents Departments of Dermatology & Radiation Oncology University of Rochester Medical.

Gibbs Regional Medical Center Spartanburg Regional Healthcare System, Spartanburg, SC.

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

Cancer Disparities Research Partnership (CDRP): Linking University & Community Radiation Oncology to Improve Cancer Outcomes Patrick D. Maguire, M.D. New.

Karen M. Mustian, Ph.D., M.P.H. Assistant Professor Director PEAK CORE Lab Department of Radiation Oncology University of Rochester Cancer Center Funding:

James D. Bearden, III, MD, FACP Principle Investigator Gibbs Cancer Center, Spartanburg, SC Gibbs Cancer Center Our NCCCP Journey 1.

Initiating phase 1 clinical trials in pediatric oncology National Cancer Institute Perspective Barry Anderson, MD, PhD Pediatric Section Cancer Therapy.

Summary of SUS Jobs Saved/Created with ARRA Funds FY *By Universities *By Special Units *By Other SUS Units.

Results of a Practice Enhancement Opportunity Assessment of FQHCs in South Carolina Practice Enhancement Opportunity Assessment Team Heather M. Brandt,

Research Orientation to SCCA. What is the SCCA? The SCCA brings together the outstanding adult and pediatric oncology patient care services of three world-

TRLN E-Resources An Evaluation and Recommendations Amanda Wilson 16 April 2004.

Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.

Evaluation Plan Steven Clauser, PhD Chief, Outcomes Research Branch Applied Research Program Division of Cancer Control and Population Sciences NCCCP Launch.

CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch

The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.

NJMS-UH Cancer Center Minority- Based Community Clinical Oncology Program.

Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee July 15, 2003 Steven Hirschfeld, MD PhD CAPT USPHS Division of Oncology Drug.

Florida Cancer Plan Phil Roland, MD FACS FACOG Florida State Chair A Commission on Cancer.

NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.

11 Radiation Therapy Oncology Group Clinical Trials Administration Sharon Hartson Stine, Director Group Administrator.

Saint Alphonsus Research Assets and Opportunities Timothy E. Sawyer, MD Radiation Oncologist Medical Director, Saint Alphonsus Cancer Care Center Founder,

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Breast Cancer Research Report SWAG Site Specific Group

Evaluating Quality in Clinical Cancer Research: The M. D

Annual Business Meeting & Class of 2017 Fellows

Progression After Cancer Immunotherapy in Advanced NSCLC

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Addressing Disease Burden in Asthma

Doctors Hospital Department of Research and Education (DORE)

Photodynamic Therapy for Early Stage Central Type of Lung Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Presentation transcript:

1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients 2) iron out how to efficiently move the most promising agents into appropriate clinical trials 3) develop a summary "position paper" to be published

Minimize DELAY and CONFUSION

Quality of life (mid 1980’s) Fatigue (2000) Curcumin (2006)

QOL and cancer in title 1980 = 2 =.05% of articles with cancer in title (cancer alone = 3966) QOL and cancer 2008 = 355 = 1.2% of articles with cancer in title (cancer alone = 29940)

June 30, 2006 IND submitted August 4, 2006 IND approved August 31, 2006 “complete clinical hold” July 25, 2007 “proceed” July 26, 2007 “hold” August 16, 2007 “approved”

Involved : 9 FDA staff 4 FDA divisions 1 FDA Ombudsman 1FDA Chief 1 US Congresswoman 1 US Senator 8 University of Rochester people And 57 separate contacts over the 412 days

What is a CCOP Research Base?  An NCI-designated Cancer Center or Cooperative Group  Funded by a Peer- Reviewed Cooperative Agreement  Develop and Conduct Cancer Prevention and Control Clinical Trials  Supports Development of Cancer Prevention Science

CCOP Research Bases: Cooperative Groups ▪ Children’s Oncology Group ▪ Cancer and Leukemia Group B ▪ Eastern Cooperative Oncology Group ▪ North Central Cancer Treatment Group ▪ Radiation Therapy Oncology Group ▪ Southwest Oncology Group ▪ National Surgical Adjuvant Breast & Bowel Project ▪ Gynecologic Oncology Group

CCOP Research Bases: Cancer Centers  H. Lee Moffitt Cancer Center  M.D. Anderson Cancer Center  University of Rochester Cancer Center  Wake Forest University Cancer Center

Central Illinois CCOPGulf Coast MBCCOPNorth Shore University Hospital CCOP Columbia River CCOPHawaii MBCCOPNorthwest CCOP Columbus CCOPHematology-Oncology of CNY CCOPSoutheast Cancer Control Consortium Dayton Clinical Oncology ProgramKalamazoo CCOPUniversity of Illinois at Chicago MBCCOP Evanston CCOPKansas City CCOPUpstate Carolina CCOP Grand Rapids CCOPMarshfield Clinic Research Foundation CCOPVirginia Mason Research Center CCOP Greenville CCOPMetro-Minnesota CCOPWichita CCOP Nevada Cancer Research Foundation CCOP CCOPs URCC UNIVERSITY OF ROCHESTER CANCER CENTER COMMUNITY CLINICAL ONCOLOGY RESEARCH BASE MAP OF AFFILIATES (2009)

What is appropriate FDA review expertise for this research? Where is it found administratively? How can mutually beneficial collaborative relationships be promoted? Is there a way to have this all be more timely?

Gary Morrow, PhD, MS URCC CCOP Research Base 20

CCOPs & [MB-CCOPs]  Accrual to Protocols  Data Management  Quality Control Research Bases ( Groups/Centers)  Develop Protocols  Data Management and Analysis  Quality Assurance Members and Affiliates  Accrual to Prevention and Control Protocols

March 2007 (50) (13) (395)